Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
HUMALOG Mix75/25 (insulin lispro protamine and insulin lispro injectable suspension) is a mixture of 75% insulin lispro protamine, an intermediate-acting human insulin analog, and 25% insulin lispro, a rapid-acting human insulin analog. Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808, both identical to that of human insulin. Insulin lispro protamine suspension is a suspension of crystals produced from combining insulin lispro and protamine sulfate under appropriate conditions for crystal formation.
Insulin lispro has the following primary structure:
 |
HUMALOG Mix75/25 vials and KwikPens contain a white and cloudy, sterile suspension of insulin lispro protamine suspension mixed with soluble insulin lispro for use as an injection.
Each milliliter of HUMALOG Mix75/25 injection contains insulin lispro 100 units, 0.28 mg protamine sulfate, 16 mg glycerin, 3.78 mg dibasic sodium phosphate, 1.76 mg Metacresol, zinc oxide content adjusted to provide 0.025 mg zinc ion, 0.715 mg phenol, and Water for Injection. The pH is 7.0 to 7.8. Sodium hydroxide and/or hydrochloric acid may be added during manufacture to adjust the pH.
HUMALOG Mix75/25 is indicated to improve glycemic control in patients with diabetes mellitus.
The proportions of rapid-acting and intermediate-acting insulins in HUMALOG Mix75/25 are fixed and do not allow for basal versus prandial dose adjustments.
HUMALOG Mix75/25 injectable suspension 100 units per mL (U100) is 75% insulin lispro protamine and 25% insulin lispro, a white and cloudy suspension available as:
HUMALOG Mix75/25 injectable suspension 100 units per mL (U100) is 75% insulin lispro protamine and 25% insulin lispro, a white and cloudy suspension available as:
| 10 mL multiple-dose vial | NDC 0002-7511-01 |
| 3 mL single-patient-use KwikPen (prefilled) | NDC 0002-8797-59 |
HUMALOG Mix75/25 injectable suspension 100 units per mL (U100) HUMALOG Mix75/25 KwikPens must never be shared between patients, even if the needle is changed. Patients using HUMALOG Mix75/25 vials must never share needles or syringes with another person. Always use a new disposable syringe or needle for each injection to prevent contamination.
The HUMALOG Mix75/25 KwikPen dials in 1 unit increments.
Do not use after the expiration date. Protect from direct heat and light. Do not freeze. See storage table below:
| Not In-Use (Unopened) Refrigerated (36° to 46°F [2° to 8°C]) | Not In Use (unopened) Room Temperature (Below 86°F [30°C]) | In-Use (Opened) Room Temperature, (Below 86°F [30°C]) | |
| 10 mL multiple-dose vial | Until expiration date | 28 days | 28 days, refrigerated/room temperature |
| 3 mL single-patient-use KwikPen | Until expiration date | 10 days | 10 days, room temperature. Do not refrigerate. |
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA, Copyright © 1999, yyyy, Eli Lilly and Company. All rights reserved. Revised: Sep 2018
The following adverse reactions are discussed elsewhere in the labeling:
The following adverse reactions have been identified during post-marketing use of HUMALOG Mix75/25. Because some of these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. Over the long-term, improved glycemic control decreases the risk of diabetic retinopathy and neuropathy.
Severe, life-threatening, generalized allergy, including anaphylaxis.
Hypoglycemia is the most commonly observed adverse reaction in HUMALOG Mix75/25.
HUMALOG Mix75/25 can cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia.
HUMALOG Mix75/25 can cause local injection site reactions including redness, swelling, or itching at the site of injection. These reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation. Localized reactions and generalized myalgias have been reported with the use of meta-cresol, which is an excipient in HUMALOG Mix75/25.
Administration of insulin subcutaneously, including HUMALOG Mix75/25, has resulted in lipoatrophy (depression in the skin) or lipohypertrophy (enlargement or thickening of tissue) [see DOSAGE AND ADMINISTRATION] in some patients.
Medication errors in which other insulins have been accidentally substituted for HUMALOG Mix75/25 have been identified during postapproval use.
Insulin, including HUMALOG Mix75/25, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.
Weight gain can occur with insulin therapy, including HUMALOG Mix75/25, and has been attributed to the anabolic effects of insulin and the decrease in glycosuria.
As with all therapeutic peptides, insulin administration may cause anti-insulin antibodies to form. The incidence of antibody formation with HUMALOG Mix75/25 is unknown.
Table 1: Clinically Significant Drug Interactions with
HUMALOG Mix75/25
| Drugs that May Increase the Risk of Hypoglycemia | |
| Drugs: | Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. |
| Intervention: | Dose adjustment and increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is co-administered with these drugs. |
| Drugs that May Decrease the Blood Glucose Lowering Effect of HUMALOG Mix75/25 | |
| Drugs: | Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. |
| Intervention: | Dose adjustment and increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is co-administered with these drugs. |
| Drugs that May Increase or Decrease the Blood Glucose Lowering Effect of HUMALOG Mix75/25 | |
| Drugs: | Alcohol, beta-blockers, clonidine, and lithium salts. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia. |
| Intervention: | Dose adjustment and increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is co-administered with these drugs. |
| Drugs that May Blunt Signs and Symptoms of Hypoglycemia | |
| Drugs: | Beta-blockers, clonidine, guanethidine, and reserpine. |
| Intervention: | Increased frequency of glucose monitoring may be required when HUMALOG Mix75/25 is coadministered with these drugs. |
Included as part of the PRECAUTIONS section.
HUMALOG Mix75/25 KwikPens must never be shared between patients, even if the needle is changed. Patients using HUMALOG Mix75/25 vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.
Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia [see Hypoglycemia] or hyperglycemia. These changes should be made cautiously and under close medical supervision and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.
Hypoglycemia is the most common adverse reaction associated with all insulin therapies, including HUMALOG Mix75/25. Severe hypoglycemia can cause seizures, may lead to unconsciousness, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).
Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic nerve disease, in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) [see DRUG INTERACTIONS], or in patients who experience recurrent hypoglycemia.
The risk of hypoglycemia after an injection is related to the duration of action of the insulin and in general, is highest when the glucose lowering effect of the insulin is maximal. As with all insulin preparations, the glucose lowering effect time course of HUMALOG Mix75/25 may vary in different individuals or at different times in the same individual and depends on many conditions, including the area of injection as well as the injection site blood supply and temperature [see CLINICAL PHARMACOLOGY]. Other factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content or timing of meals), changes in level of physical activity, or changes to coadministered medication [see DRUG INTERACTIONS]. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia [see Use In Specific Populations].
Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
Accidental mix-ups between HUMALOG Mix75/25 and other insulin products have been reported. To avoid medication errors between HUMALOG Mix75/25 and other insulins, instruct patients to always check the insulin label before each injection.
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including HUMALOG Mix75/25. If hypersensitivity reactions occur, discontinue HUMALOG Mix75/25; treat per standard of care and monitor until symptoms and signs resolve. HUMALOG Mix75/25 is contraindicated in patients who have had hypersensitivity reactions to HUMALOG Mix75/25 or any of its excipients [see CONTRAINDICATIONS].
All insulin products, including HUMALOG Mix75/25, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated (e.g., patients using potassiumlowering medications, patients taking medications sensitive to serum potassium concentrations).
Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including HUMALOG Mix75/25, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Advise patients using Humalog Mix75/25 vials or Humalog Mix75/25 KwikPen not to share needles, syringes, or KwikPen with another person. Sharing poses a risk for transmission of blood-borne pathogens.
Inform patients that hypoglycemia is the most common adverse reaction with insulin. Instruct patients on selfmanagement procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia, especially at initiation of HUMALOG Mix75/25 therapy. Instruct patients on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Instruct patients on the management of hypoglycemia [see WARNINGS AND PRECAUTIONS].
Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery.
Instruct patients to always check the insulin label before each injection to avoid mix-ups between insulin products [see WARNINGS AND PRECAUTIONS].
Advise patients that hypersensitivity reactions have occurred with HUMALOG Mix75/25. Inform patients on the symptoms of hypersensitivity reactions and to seek medical attention if they occur [see WARNINGS AND PRECAUTIONS].
Standard 2-year carcinogenicity studies in animals have not been performed with HUMALOG Mix75/25. In Fischer 344 rats, a 12-month repeat-dose toxicity study was conducted with insulin lispro (a component of HUMALOG Mix75/25) at subcutaneous doses of 20 and 200 units/kg/day (approximately 3 and 32 times the human subcutaneous dose of 1 unit insulin lispro/kg/day, based on units/body surface area). Insulin lispro did not produce important target organ toxicity including mammary tumors at any dose.
Insulin lispro was not mutagenic in the following genetic toxicity assays: bacterial mutation, unscheduled DNA synthesis, mouse lymphoma, chromosomal aberration and micronucleus assays.
Male fertility was not compromised when male rats given subcutaneous insulin lispro injections of 5 and 20 units/kg/day (0.8 and 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day, based on units/body surface area) for 6 months were mated with untreated female rats. In a combined fertility, perinatal, and postnatal study in male and female rats given 1, 5, and 20 units/kg/day subcutaneously (0.16, 0.8, and 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day, based on units/body surface area), mating and fertility were not adversely affected in either gender at any dose.
The limited available data with HUMALOG Mix75/25 in pregnant women are insufficient to inform a drugassociated risk of adverse developmental outcomes. Published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations).
Pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. No adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed to insulin lispro at a dose approximately 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day. No adverse effects on embryo/fetal development were observed in offspring of rabbits exposed to insulin lispro at doses up to approximately 0.24 times the human subcutaneous dose of 1 unit/kg/day (see Data).
The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Disease-Associated Maternal And/Or Embryo/Fetal Risk
Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity.
Human Data
Published data from retrospective studies and meta-analyses do not report an association with insulin lispro and major birth defects, miscarriage, or adverse maternal or fetal outcomes when insulin lispro is used during pregnancy. However, these studies cannot definitely establish or exclude the absence of any risk because of methodological limitations including small sample size, selection bias, confounding by unmeasured factors, and some lacking comparator groups.
Animal Data
Animal reproduction studies have not been performed with HUMALOG Mix75/25. However, subcutaneous reproduction and teratology studies have been conducted with insulin lispro (a component of HUMALOG Mix75/25). In a combined fertility and embryo-fetal development study, female rats were given subcutaneous insulin lispro injections of 5 and 20 units/kg/day (0.8 and 3 times the human subcutaneous dose of 1 unit insulin lispro/kg/day, based on units/body surface area, respectively) from 2 weeks prior to cohabitation through Gestation Day 19. There were no adverse effects on female fertility, implantation, or fetal viability and morphology. However, fetal growth retardation was produced at the 20 units/kg/day-dose as indicated by decreased fetal weight and an increased incidence of fetal runts/litter.
In an embryo-fetal development study in pregnant rabbits, insulin lispro doses of 0.1, 0.25, and 0.75 unit/kg/day (0.03, 0.08, and 0.24 times the human subcutaneous dose of 1 unit insulin lispro/kg/day, based on units/body surface area, respectively) were injected subcutaneously on Gestation days 7 through 19. There were no adverse effects on fetal viability, weight, and morphology at any dose.
There are no data on the presence of HUMALOG Mix75/25 in human milk, the effects on the breastfed infant, or the effect on milk production. One small published study reported that exogenous insulin was present in human milk. However, there is insufficient information to determine the effects of HUMALOG Mix75/25 on the breastfed infant and no available information on the effects of HUMALOG Mix75/25 on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for insulin, any potential adverse effects on the breastfed child from HUMALOG Mix75/25 or from the underlying maternal condition.
Safety and effectiveness of HUMALOG Mix75/25 in patients less than 18 years of age has not been established.
Clinical studies of Humalog Mix75/25 did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. In elderly patients with diabetes, the initial dosing, dose increments, and maintenance dosage should be conservative to reduce the risk of hypoglycemia [see WARNINGS AND PRECAUTIONS].
The effect of renal impairment on the pharmacokinetics of HUMALOG Mix75/25 has not been studied. Patients with renal impairment may be at increased risk of hypoglycemia and may require more frequent HUMALOG Mix75/25 dose adjustment and more frequent glucose monitoring [see WARNINGS AND PRECAUTIONS].
The effect of hepatic impairment on the pharmacokinetics of HUMALOG Mix75/25 has not been studied. Patients with hepatic impairment may be at increased risk of hypoglycemia and may require more frequent HUMALOG Mix75/25 dose adjustment and more frequent glucose monitoring [see WARNINGS AND PRECAUTIONS].
Excess insulin administration may cause hypoglycemia and hypokalemia. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular or subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately [see WARNINGS AND PRECAUTIONS].
HUMALOG Mix75/25 is contraindicated:
The primary activity of insulin, including HUMALOG Mix75/25, is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
In a glucose clamp study performed in 30 healthy subjects, the onset of action and glucose-lowering activity of HUMALOG, HUMALOG® Mix50/50™, HUMALOG Mix75/25, and insulin lispro protamine suspension (ILPS) were compared (see Figure 1). Graphs of mean glucose infusion rate versus time showed a distinct insulin activity profile for each formulation. The rapid onset of glucose-lowering activity characteristic of HUMALOG was maintained in HUMALOG Mix75/25. The median maximum pharmacologic effect of HUMALOG Mix75/25 after administration of a 0.3 unit/kg dose to healthy subjects occurred at approximately 2 hours (range: 1-6 hours); glucose lowering activity was detectable for a median of 22 hours (range: 13 to 22 hours), which was the end of the clamp.
In separate glucose clamp studies performed in healthy subjects, pharmacodynamics of HUMALOG Mix75/25 and HUMULIN® 70/30 were assessed and are presented in Figure 2. HUMALOG Mix75/25 has a duration of activity similar to that of HUMULIN 70/30.
Figures 1 and 2 should be considered only as representative examples since the time course of action of insulin and insulin analogs, may vary in different individuals or within the same individual.
Figure 1: Mean Insulin Activity Versus Time Profiles
After Injection of 0.3 units/kg of HUMALOG, HUMALOG Mix50/50, HUMALOG Mix75/25,
or Insulin Lispro Protamine Suspension (ILPS) in 30 Healthy Subjects.
 |
Figure 2: Mean Insulin Activity Versus Time Profiles
After Injection of 0.3 units/kg of HUMALOG Mix75/25 or HUMULIN 70/30 in Healthy
Subjects.
 |
HUMALOG Mix75/25 has two phases of absorption. The early phase represents insulin lispro and its distinct characteristics of rapid onset. The late phase represents the prolonged absorption of insulin lispro protamine suspension.
In 31 healthy subjects given subcutaneous doses (0.3 unit/kg) of HUMALOG Mix75/25, the median peak serum concentration was 60 minutes (range: 30 minutes to 4 hours) after dosing. Identical results were found in patients with type 1 diabetes. The rapid absorption characteristics of HUMALOG are maintained with HUMALOG Mix75/25. HUMALOG Mix75/25 has a more rapid absorption than HUMULIN 70/30, which has been confirmed in patients with type 1 diabetes.
Human metabolism studies of HUMALOG Mix75/25 have not been conducted. However, studies in animals indicate that the metabolism of HUMALOG, the rapid-acting component of HUMALOG Mix75/25, is identical to that of regular human insulin.
Because of the absorption-rate limited kinetics of insulin mixtures, a true half-life cannot be accurately estimated from the terminal slope of the concentration versus time curve.
The effects of age, race, obesity, pregnancy, smoking, or renal or hepatic impairment on the pharmacokinetics of HUMALOG Mix75/25 have not been studied.
Pharmacokinetic and pharmacodynamic comparisons between men and women administered HUMALOG Mix75/25 showed no gender differences.
HUMALOG® (HU-ma-log) Mix75/25™
(insulin lispro protamine and insulin lispro injectable suspension) for
subcutaneous use
Do not share your HUMALOG Mix75/25 KwikPen, needles or syringes with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
What is HUMALOG Mix75/25?
Who should not take HUMALOG Mix75/25?
Do not take HUMALOG Mix75/25 if you:
What should I tell my healthcare provider before taking Humalog Mix75/25?
Before taking HUMALOG Mix75/25, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Before you start taking HUMALOG Mix75/25, talk to your healthcare provider about low blood sugar and how to manage it.
How should I take HUMALOG Mix75/25?
Keep HUMALOG Mix75/25 and all medicines out of the reach of children.
Your dose of HUMALOG Mix75/25 may need to change because of a:
What should I avoid while taking HUMALOG Mix75/25?
While taking HUMALOG Mix75/25 do not:
What are the possible side effects of HUMALOG Mix75/25?
HUMALOG Mix75/25 may cause serious side effects that can lead to death, including:
Your healthcare provider may prescribe a glucagon emergency kit so that someone else can give you glucagon if your blood sugar becomes too low (severe hypoglycemia) and you are unable to take sugar by mouth.
Treatment with TZDs and HUMALOG Mix75/25 may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure.
Get emergency medical help if you have:
The most common side effects of HUMALOG Mix75/25 include:
These are not all the possible side effects of HUMALOG Mix75/25. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of HUMALOG Mix75/25.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take HUMALOG Mix75/25 for a condition for which it was not prescribed. Do not give HUMALOG Mix75/25 to other people, even if they have the same symptoms that you have. It may harm them.
This Patient Information leaflet summarizes the most important information about HUMALOG Mix75/25. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about HUMALOG Mix75/25 that is written for health professionals.
What are the ingredients in HUMALOG Mix75/25?
Active ingredients: insulin lispro
Inactive ingredients: protamine sulfate, glycerin, dibasic sodium phosphate, metacresol, zinc oxide (zinc ion), phenol and water for injection.
Instructions for Use
HUMALOG® (HU-ma-log) Mix75/25™
(insulin lispro protamine and insulin lispro injectable suspension) for
subcutaneous use 10 mL vial (100 units/mL)
Read this Instructions for Use before you start taking HUMALOG Mix75/25 and each time you get a new vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your needles or syringes with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
Supplies needed to give your injection
 |
Preparing your HUMALOG Mix75/25 dose
Step 1:
Gently roll the vial between the palms of your hands at least 10 times.
 |
Step 2:
Gently move the vial up and down (invert) at least 10 times.
Mixing is important to make sure you get the right dose. Humalog Mix75/25 should look white and cloudy after mixing. Do not use it if it looks clear or contains any lumps or particles.
 |
Step 3:
If you are using a new vial, pull off the plastic Protective Cap, but do not remove the Rubber Stopper.
 |
Step 4:
Wipe the Rubber Stopper with an alcohol swab.
 |
Step 5:
Remove the Needle Shield from the syringe by pulling the Needle Shield straight off. Hold the syringe with the needle pointing up. Pull down on the Plunger until the Plunger Tip reaches the line for the number of units for your prescribed dose.
 |
Step 6:
Push the needle through the Rubber Stopper of the vial.
 |
Step 7:
Push the Plunger all the way in. This puts air into the vial.
 |
Step 8:
Turn the vial and syringe upside down and slowly pull the Plunger down until the Plunger
Tip is a few units past the line for your prescribed dose.
 |
If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.
 |
Step 9:
Slowly push the Plunger up until the Plunger Tip reaches the line for your prescribed dose.
Check the syringe to make sure that you have the right dose.
 |
Step 10:
Pull the syringe out of the Rubber Stopper of the vial.
 |
Giving your HUMALOG Mix75/25 Injection
Step 11:
Choose your injection site.
HUMALOG Mix75/25 is injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs or upper arms.
Wipe the skin with an alcohol swab. Let the injection site dry before you inject your dose.
 |
Step 12:
Insert the needle into your skin.
 |
Step 13:
Push down on the Plunger to inject your dose.
The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your insulin dose.
 |
Step 14:
Pull the needle out of your skin.
 |
Disposing of used needles and syringes
How should I store HUMALOG Mix75/25?
All unopened vials:
After vials have been opened:
Keep HUMALOG Mix75/25 vials, syringes, needles, and all medicines out of the reach of children.
If you have any questions or problems with your HUMALOG, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help. For more information on HUMALOG and insulin, go to www.humalog.com.Scan this code to launch the humalog.com website
Instructions for Use
HUMALOG® (HU-ma-log) Mix75/25™ KwikPen®
(insulin lispro protamine and insulin lispro injectable suspension) for
subcutaneous use 3 mL pen (100 units/mL)
 |
Read this Instructions for Use before you start taking HUMALOG Mix75/25 and each time you get another KwikPen. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
Do not share your HUMALOG Mix75/25 KwikPen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
HUMALOG Mix75/25 KwikPen (“Pen”) is a disposable prefilled pen containing 300 units of HUMALOG Mix75/25.
People who are blind or have vision problems should not use this Pen without help from a person trained to use the Pen.
 |
Pen Needle Parts (Needles Not Included)
 |
How to recognize your HUMALOG Mix75/25 KwikPen
Supplies you will need to give your injection
Preparing your Pen
Step 1:
 |
Step 2:
 |
Step 3:
Step 4:
 |
Step 5:
 |
Step 6:
 |
Step 7:
 |
Priming your Pen
Prime your Pen before each injection.
Step 8:
 |
Step 9:
 |
Step 10:
Small air bubbles are normal and will not affect your dose.
 |
Selecting your dose
Step 11:
 |
Giving your injection
Step 12:
 |
Step 13:
 |
 |
Do not try to inject your insulin by turning the Dose Knob. You will not receive your insulin by turning the Dose Knob.
Step 14:
The Plunger only moves a little with each injection, and you may not notice that it moves.
If you see blood after you take the Needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. Do not rub the area.
 |
After your injection
Step 15:
 |
Step 16:
 |
Step 17:
 |
Disposing of Pens and Needles
The used Pen may be discarded in your household trash after you have removed the needle.
Storing your Pen
Unused Pens
In-use Pen
General information about the safe and effective use of your Pen
Troubleshooting
If you have any questions or problems with your HUMALOG Mix75/25 KwikPen, contact Lilly at 1- 800-LillyRx (1-800-545-5979) or call your healthcare provider for help. For more information on HUMALOG Mix75/25 KwikPen and insulin, go to www.humalog.com. Scan this code to launch www.humalog.com
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
